Immunoprecise Antibodies Ltd Stock Other OTC
Stocks
CA87588T1030
Pharmaceuticals
| Market Cap | 89.47M 63.53M 55.8M 51.89M 47.62M 6.12B 90.85M 616M 241M 3.01B 238M 233M 10.4B | P/E 2027 * |
-6.12x | P/E 2028 * | -8x |
|---|---|---|---|---|---|
| Enterprise Value | 89.47M 63.53M 55.8M 51.89M 47.62M 6.12B 90.85M 616M 241M 3.01B 238M 233M 10.4B | EV / Sales 2027 * |
4.42x | EV / Sales 2028 * | 3.59x |
| Free-Float |
91.03% | Yield 2027 * |
-
| Yield 2028 * | - |
Last Transcript: Immunoprecise Antibodies Ltd
| 1 day | -6.29% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 2018-02-20 |
Richard Areglado
DFI | Director of Finance/CFO | 62 | 2025-10-19 |
Hyfte Van
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
BRD | Director/Board Member | - | 2018-05-23 |
Dirk Witters
CHM | Chairman | - | - |
Jonathan Lieber
BRD | Director/Board Member | 56 | 2025-07-06 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.29% | -23.22% | - | - | 63.53M | |
| +2.44% | -0.50% | +19.71% | -10.19% | 66.74B | |
| +0.12% | +3.49% | +37.71% | +204.60% | 53.32B | |
| +10.08% | +51.80% | +51.80% | +51.80% | 48.12B | |
| +1.90% | -5.07% | -56.99% | -56.52% | 38.25B | |
| +0.66% | +1.60% | +57.13% | -22.70% | 29.85B | |
| +2.29% | +3.44% | +70.51% | +90.86% | 23.51B | |
| +5.09% | -5.65% | +65.53% | -52.64% | 21.45B | |
| +1.86% | +5.79% | +84.82% | +165.92% | 16.47B | |
| +1.31% | -0.13% | +64.09% | +126.00% | 16.38B | |
| Average | +1.94% | -0.72% | +43.81% | +55.24% | 34.9B | |
| Weighted average by Cap. | +3.06% | +0.01% | +34.56% | +49.94% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 20.24M 14.38M 12.63M 11.74M 10.77M 1.38B 20.56M 139M 54.47M 681M 53.97M 52.8M 2.35B | 24.9M 17.68M 15.53M 14.44M 13.25M 1.7B 25.28M 171M 66.99M 837M 66.37M 64.94M 2.89B |
| Net income | -14.81M -10.52M -9.24M -8.59M -7.88M -1.01B -15.04M -102M -39.86M -498M -39.49M -38.63M -1.72B | -11.81M -8.38M -7.36M -6.85M -6.28M -807M -11.99M -81.31M -31.77M -397M -31.47M -30.79M -1.37B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
